Visceral disease in castration-resistant prostate cancer

Carmel Jo Pezaro, Aurelius Omlin, David Lorente, Daniel Nava Rodrigues, Roberta Ferraldeschi, Diletta Bianchini, Deborah Mukherji, Ruth Riisnaes, Amelia Altavilla, Mateus Crespo, Nina Tunariu, Johann S De Bono, Gerhardt Attard

Research output: Contribution to journalArticleResearchpeer-review

101 Citations (Scopus)

Abstract

Metastatic involvement of the viscera in men with advanced castration-resistant prostate cancer (CRPC) has been poorly characterised to date. In 359 CRPC patients treated between June 2003 and December 2011, the frequency of radiologically detected visceral metastases before death was 32%. Of the 92 patients with computed tomography performed within 3 mo of death, 49% had visceral metastases. Visceral metastases most commonly involved the liver (20%) and lung (13%). Median survival from diagnosis of visceral disease was 7.1 mo (95% confidence interval, 5.9-8.3). Survival was affected by the degree of bone involvement at detection of visceral disease, varying from 6.1 mo in men with more than six bone metastases to 18.2 mo in men with no bone metastases (p = 0.001). Heterogeneity was noted in clinical phenotypes and prostate-specific antigen trends at development of visceral metastases. Visceral metastases are now more commonly detected in men with CRPC, likely due to the introduction of novel survival-prolonging treatments.
Original languageEnglish
Pages (from-to)270-273
Number of pages4
JournalEuropean Urology
Volume65
DOIs
Publication statusPublished - 2014
Externally publishedYes

Cite this

Pezaro, C. J., Omlin, A., Lorente, D., Rodrigues, D. N., Ferraldeschi, R., Bianchini, D., Mukherji, D., Riisnaes, R., Altavilla, A., Crespo, M., Tunariu, N., De Bono, J. S., & Attard, G. (2014). Visceral disease in castration-resistant prostate cancer. European Urology, 65, 270-273. https://doi.org/10.1016/j.eururo.2013.10.055